# | Title | Journal | Year | Citations |
---|
|
1 | The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Alzheimer's and Dementia | 2011 | 13,319 |
2 | The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Alzheimer's and Dementia | 2011 | 7,876 |
3 | NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease | Alzheimer's and Dementia | 2018 | 6,501 |
4 | Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Alzheimer's and Dementia | 2011 | 5,740 |
5 | The global prevalence of dementia: A systematic review and metaanalysis | Alzheimer's and Dementia | 2013 | 3,784 |
6 | Forecasting the global burden of Alzheimer's disease | Alzheimer's and Dementia | 2007 | 2,738 |
7 | National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Alzheimer's and Dementia | 2012 | 2,089 |
8 | A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease | Alzheimer's and Dementia | 2014 | 2,006 |
9 | Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Alzheimer's and Dementia | 2011 | 1,602 |
10 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria | Alzheimer's and Dementia | 2016 | 1,412 |
11 | Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population‐based perspective | Alzheimer's and Dementia | 2015 | 1,259 |
12 | Neuroinflammation in Alzheimer's disease: Current evidence and future directions | Alzheimer's and Dementia | 2016 | 1,175 |
13 | Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI) | Alzheimer's and Dementia | 2005 | 964 |
14 | Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance | Alzheimer's and Dementia | 2020 | 907 |
15 | 2012 Alzheimer's disease facts and figures Alzheimer's Association∗ | Alzheimer's and Dementia | 2012 | 887 |
16 | Neuropsychiatric symptoms in Alzheimer's disease | Alzheimer's and Dementia | 2011 | 805 |
17 | The worldwide economic impact of dementia 2010 | Alzheimer's and Dementia | 2013 | 804 |
18 | The worldwide costs of dementia 2015 and comparisons with 2010 | Alzheimer's and Dementia | 2017 | 798 |
19 | MIND diet associated with reduced incidence of Alzheimer's disease | Alzheimer's and Dementia | 2015 | 725 |
20 | Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years | Alzheimer's and Dementia | 2019 | 713 |
21 | Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study | Alzheimer's and Dementia | 2015 | 699 |
22 | The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET | Alzheimer's and Dementia | 2015 | 690 |
23 | MIND diet slows cognitive decline with aging | Alzheimer's and Dementia | 2015 | 674 |
24 | Defining imaging biomarker cut points for brain aging and Alzheimer's disease | Alzheimer's and Dementia | 2017 | 653 |
25 | Inequalities in dementia incidence between six racial and ethnic groups over 14 years | Alzheimer's and Dementia | 2016 | 606 |
26 | The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception | Alzheimer's and Dementia | 2013 | 568 |
27 | Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment | Alzheimer's and Dementia | 2016 | 532 |
28 | CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts | Alzheimer's and Dementia | 2018 | 526 |
29 | Understanding the impact of sex and gender in Alzheimer's disease: A call to action | Alzheimer's and Dementia | 2018 | 526 |
30 | [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease | Alzheimer's and Dementia | 2013 | 523 |
31 | Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060) | Alzheimer's and Dementia | 2021 | 487 |
32 | Vascular dysfunction—The disregarded partner of Alzheimer's disease | Alzheimer's and Dementia | 2019 | 476 |
33 | Vascular contributions to cognitive impairment and dementia including Alzheimer's disease | Alzheimer's and Dementia | 2015 | 475 |
34 | The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core | Alzheimer's and Dementia | 2010 | 473 |
35 | Outcome over seven years of healthy adults with and without subjective cognitive impairment | Alzheimer's and Dementia | 2010 | 462 |
36 | The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans | Alzheimer's and Dementia | 2010 | 462 |
37 | Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association | Alzheimer's and Dementia | 2013 | 459 |
38 | The cost of Alzheimer's disease in China and re‐estimation of costs worldwide | Alzheimer's and Dementia | 2018 | 459 |
39 | Consensus classification of posterior cortical atrophy | Alzheimer's and Dementia | 2017 | 453 |
40 | Core candidate neurochemical and imaging biomarkers of Alzheimer's disease | Alzheimer's and Dementia | 2008 | 452 |
41 | Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive decline | Alzheimer's and Dementia | 2010 | 450 |
42 | Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis | Alzheimer's and Dementia | 2017 | 450 |
43 | Mild cognitive impairment: Disparity of incidence and prevalence estimates | Alzheimer's and Dementia | 2012 | 446 |
44 | At the interface of sensory and motor dysfunctions and Alzheimer's disease | Alzheimer's and Dementia | 2015 | 445 |
45 | The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception | Alzheimer's and Dementia | 2012 | 439 |
46 | Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting | Alzheimer's and Dementia | 2013 | 435 |
47 | Molecular genetics of early‐onset Alzheimer's disease revisited | Alzheimer's and Dementia | 2016 | 435 |
48 | Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome | Alzheimer's and Dementia | 2019 | 435 |
49 | AD dementia risk in late MCI, in early MCI, and in subjective memory impairment | Alzheimer's and Dementia | 2014 | 429 |
50 | Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography | Alzheimer's and Dementia | 2018 | 427 |